Ceevra is a technology company.
Ceevra has raised $2.9M across 2 funding rounds.
Ceevra has raised $2.9M in total across 2 funding rounds.
Ceevra, Inc. is an advanced surgical visualization company that uses FDA-cleared machine learning and computer vision to convert standard CT and MRI scans into interactive, patient-specific 3D digital models for preoperative planning.[1][2][3] It serves hospitals, academic medical centers, and health systems—such as AdventHealth, UCLA Health, and Baptist Health South Florida—performing complex surgeries in specialties like thoracic, urologic, general, HPB, and gynecologic procedures.[1][2][5] Ceevra solves the limitations of 2D imaging by providing surgeons with detailed 3D views of anatomy, enabling better surgical planning, reduced operative time, lower blood loss, shorter hospital stays, and improved patient outcomes, as shown in randomized clinical trials like one on robotic partial nephrectomy published in JAMA Network Open.[1][2][5] Its models have supported nearly 3,000 operations worldwide, with easy cloud-based generation (within two business days) viewable on phones, tablets, laptops, or robotic displays, requiring minimal hospital effort.[1][2][4]
Growth momentum includes pioneering FDA 510(k) clearance in 2023 as the first ML-based software for 3D surgical planning in urologic and thoracic procedures, plus CE Marking for broad surgical use.[1][3]
Ceevra was founded in 2016 in San Francisco to improve cancer operations by applying cloud, mobile, and computer vision technologies to medical imaging.[3] Led by CEO Russ Yoshinaka, the company emerged from the need to overcome 2D imaging's shortcomings in complex surgeries, developing fully automated 3D models generated in the cloud without manual input.[1][3][4] Early traction came from adoption by leading institutions; for instance, AdventHealth became Florida's first commercial adopter in December 2019, using it for kidney tumor cases where 3D models revealed tumor locations invisible in 2D scans.[5] Pivotal moments include the 2023 FDA clearance for AI-powered software, marking it as an industry first for ML-generated 3D images in key surgical specialties.[3]
Ceevra rides the wave of AI-driven precision medicine and surgical robotics, where market forces like rising complex cancer surgeries, robotic adoption (e.g., da Vinci systems), and demand for better outcomes favor automated 3D visualization.[1][2][3] Timing is ideal post-2023 FDA clearance, as hospitals seek workflow-integrated tools amid labor shortages and value-based care pressures—its no-effort model scales across specialties without specialized staff.[4] It influences the ecosystem by setting standards for AI in imaging (first ML-cleared for planning), enabling data-driven decisions that cut costs and improve equity in surgical access, while supporting patient-centric trends like informed consent via visuals.[2][5]
Ceevra is positioned to expand as AI surgical intelligence becomes standard, with ongoing development targeting robotic and complex procedures; expect broader specialty coverage, deeper integrations with robotic platforms, and more trials validating outcomes.[1][3] Trends like generative AI for imaging and personalized medicine will accelerate adoption, potentially making 3D models routine in cancer ops and boosting revenue via subscriptions at top health systems.[2][4] Its influence may evolve from niche innovator to ecosystem enabler, as surgeons rely on it for safer, faster interventions—ultimately transforming preoperative planning from art to precision science, much like its origin vision for modernized cancer surgery.[3]
Ceevra has raised $2.9M in total across 2 funding rounds.
Ceevra's investors include Aegon Asset Management, Flex Capital, Freestyle Capital, General Catalyst, M.G. Siegler, Nyca Partners, Richmond Global Ventures, Seven Seven Six, Y Combinator, Aaron Harris, Eoghan McCabe, Eric Ries.
Ceevra has raised $2.9M across 2 funding rounds. Most recently, it raised $930K Seed in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $930K Seed | Aegon Asset Management, Flex Capital, Freestyle Capital, General Catalyst, M.G. Siegler, Nyca Partners, Richmond Global Ventures, Seven Seven Six, Y Combinator, Aaron Harris, Eoghan McCabe, Eric Ries, Leonardo DiCaprio, Louis Beryl, Marc Benioff, MG Siegler | |
| Mar 1, 2018 | $2.0M Seed | Aegon Asset Management, Airtree Ventures, BEENEXT, Blackbird Ventures Australia, Craft Ventures, Flex Capital, Freestyle Capital, General Catalyst, Gigafund, M.G. Siegler, LAUNCH, Jeff Richards, Nyca Partners, Polychain Capital, Richmond Global Ventures, Sequoia Capital, Seven Seven Six, SOSV, TSVC Capital, Y Combinator, Aaron Harris, Aston Motes, Eoghan McCabe, Eric Ries, Henry Kravis, Kamiar Kordari, Leonardo DiCaprio, Louis Beryl, Marc Benioff, MG Siegler, Michael Stoppelman, Namrata Ganatra, Rick Berry, Steve King, Steven Tamm, Tyler Willis |